Solstice Oncology has secured $225 million in series A funds to advance a next-gen immunotherapy that the biotech hopes will turn “darkness to light” for cancer care.
- Home |
- Solstice rises with $225M series A to advance next-gen CTLA-4 immunotherapy into phase 2
Solstice rises with $225M series A to advance next-gen CTLA-4 immunotherapy into phase 2
- September 9, 2026
Recent Posts
- LNG market tightens into winter as Europe pulls US cargoes, China reopens contract talks
- EIA: US crude oil inventories down 3.2 million bbl
- Chevron restructures Bakken midstream agreements, transfers Hess Midstream stake
- Cenovus to build oil sands business via Athabasca acquisition
- Centalion acquires Haynesville gas assets from Silver Hill
